Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

Launched by DEPARTMENT OF MEDICAL SERVICES MINISTRY OF PUBLIC HEALTH OF THAILAND · Sep 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well two treatments—Tranexamic Acid and Estrogen—can help women who experience abnormal uterine bleeding after receiving a birth control injection called Depo-medroxyprogesterone acetate (DMPA). Abnormal bleeding is a common reason why women stop using DMPA, and this study aims to find out which treatment works better to stop that bleeding.

To be eligible for this trial, participants need to be women aged 18 to 45 who have been experiencing abnormal bleeding for more than 7 days after their first DMPA injection. It's important that they can understand Thai and give their consent to participate. However, women with certain health conditions, such as high blood pressure or a history of blood clots, cannot join the study. If eligible, participants will receive one of the treatments and will be closely monitored to see how well it helps with their bleeding. This research hopes to improve care for women facing this issue.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Abnormal uterine bleeding more than 7 days after first DMPA injection
• • Provide inform consent with patient
• • Can understand thai language
• Exclusion Criteria:
• • Have contraindication to use Tranexamic acid and estrogen such as hypertension, Stroke, MI, DM, Renal disease, Liver disease, CA breast etc.
• • Have pathology in uterus from pelvic examination, pap smear and ultrasound
• • Current pelvic infection
• • Postpartum less than 6 months
• • History deep vein thrombosis
• • Breastfeeding